W. Halota

Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

M. Leshno, J. Mossong, C. Stedman, 2015, Journal of viral hepatitis.

Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: Epi-Ter2 study

K. Simon, A. Horban, E. Janczewska, 2020, AIDS care.

Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals

R. Flisiak, B. Mroczko, M. Krintus, 2019, British journal of biomedical science.

The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection

A. Tretyn, K. Domagalski, M. Pawłowska, 2014, European Journal of Clinical Microbiology & Infectious Diseases.

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

M. Leshno, J. Mossong, C. Stedman, 2015, Journal of viral hepatitis.

HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B

M. Pawłowska, W. Halota, M. Pawłowska, 2011, European Journal of Clinical Microbiology & Infectious Diseases.

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2

M. Leshno, J. Mossong, C. Stedman, 2015, Journal of viral hepatitis.

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4

T. Grzybowski, A. Tretyn, K. Domagalski, 2013, European Journal of Clinical Microbiology & Infectious Diseases.

Treatment of HCV infection in Poland at the beginning of the interferon‐free era—the EpiTer‐2 study

K. Simon, M. Pawłowska, A. Horban, 2018, Journal of viral hepatitis.